From: Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis
Healthy subjects | Untreated IPF | Treated IPF | |
---|---|---|---|
IGF-1 (ng/ml) | 31 (7–67) | 20 (9–102)* | 25 (11–57) |
IGF-2 (ng/ml) | 710 (401–2232) | 590 (210–1027)* | 586 (282–920)** |
IGFBP-1 (ng/ml) | 11 (0–180) | 22 (4–110)* | 9 (1–107) |
IGFBP-2 (ng/ml) | 94 (34–211) | 206 (113–317)*** | 153 (32–291)** ° |
IGFBP-3 (ng/ml) | 2132 (1207–4059) | 1536 (534–2556)* | 2032 (893–3505) |
Molar ratio IGF-1 : IGFBP-1 | 12 (1–314) | 3,5 (0,3–36,3)* | 9 (1–152) |
Molar ratio IGF-1 : IGFBP-2 | 1,8 (0,2–6,2) | 0,4 (0–4,3)*** | 0,7 (0,3–5,2)* |
Molar ratio IGF-1 : IGFBP-3 | 0,06 (0,02–0,12) | 0,05 (0,03–0,25) | 0,05 (0,03–0,1) |
Molar ratio IGF-2 : IGFBP-1 | 247 (20–6735) | 110 (11–769)* | 259 (20–2429) |
Molar ratio IGF-2 : IGFBP-2 | 40 (10–202) | 14 (5–28)*** | 19 (7–89)** |
Molar ratio IGF-2 : IGFBP-3 | 1,4 (0,8-5,1) | 1,6 (0,6-2,2) | 1,2 (0,9-1,8) |
TGF-β (ng/ml) | 11 (3–21) | 11 (5–22) | 9 (4–17) |
KL-6 (ng/ml) | 262 (83–596) | 1050 (314–4951)*** | 889 (359–6168)*** |